@Article{Marzec-Kotarska2011,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="10",
number="2",
year="2011",
title="Podoplanin expression in malignant ovarian cancer",
abstract="  Introduction:   Ovarian cancer is mostly diagnosed in postmenopausal women. The hormonal microenviron-  ment of ovarian tumour development in pre- and postmenopausal women is different. The environment may influence the molecular basis of ovarian cancer. Podoplanin is a proven marker of lymphangiogenesis and is engaged in tumour progression and metastasis.     Objectives:   The aim of our study was to assess podoplanin expression at the mRNA level in ovarian serous and mucinous adenocarcinoma.     Material and methods  : mRNA expression of podoplanin was assessed in 42 ovarian cancer patients by means of real-time PCR.     Results  : Podoplanin was expressed at the mRNA level in all ovarian cancer patients. It was significantly lower (p < 0.001) in cancer tissues (RQ = 4.46) than in healthy control (RQ = 13.03). No significant differences were found in podoplanin expression either between pre- and postmenopausal women or in relation to FIGO and grading    Conclusion  : Decreased podoplanin expression is characteristic for serous and mucinous ovarian adenocarcinoma.",
author="Marzec-Kotarska, Barbara
and Kotarski, Józef
and Cybulski, Marek
and Antosz, Halina
and Kocki, Janusz
and Bednarek, Wiesława",
pages="102--105",
url="https://www.termedia.pl/Podoplanin-expression-in-malignant-ovarian-cancer,4,16611,1,1.html"
}